340B hospitals among those that provide lowest levels of community benefit across the country

The 340B program reached$38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014. Unfortunately, despite pharmaceutical manufacturers paying more and more money in 340B discounts, there is no evidence that this growth in 340B translates into lower costs for patients taking prescription medicines.
Source: The Catalyst - Category: Pharmaceuticals Tags: 340B Hospitals Source Type: news